Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The renin-angiotensin-aldosterone system (RAAS), whose major vasopressor effector is angiotensin II (ATII), has multiple activities and regulates sodium-water homeostasis and fluid and blood pressure homeostasis. RAAS plays a crucial role in cardiocirculatory shock because it counteracts hypotension and hypovolemia by activating different physiologic responses. Based on the encouraging results of the ATHOS-3 trial, the US Food and Drug Administration and the European Medicines Agency approved the use of ATII for catecholamine-resistant vasodilatory shock. More recently, ATII was used for the compassionate treatment of critically ill patients with COVID-19. Beyond its vasopressor properties, ATII was hypothesized to have antiviral activity because it induces internalization and degradation of angiotensin-converting enzyme 2 receptors used by SARS-CoV-2 to infect cells. Overall, the use of ATII in patients with COVID-19 showed promising results because its administration was associated with the achievement and maintenance of target mean arterial pressure, increased $P_{A\text{O}_2}/F_{\text{I\text{O}_2}}$ ratio, and decreased $F_{\text{I\text{O}_2}}$. The aim of this narrative review is to summarize the available knowledge on the use of ATII in patients with COVID-19.

© 2022 Elsevier Inc. All rights reserved.

**Key Words:** angiotensin-II; vasopressor; COVID-19; shock

Two-thirds of ventilated patients with COVID-19 develop distributive shock requiring vasopressor support. The recent approval by the US Food and Drug Administration and European Medicines Agency of angiotensin II (ATII) for vasodilatory shock marks a potential turning point in the treatment of hypotensive critically ill patients with COVID-19. The rationale behind the use of ATII in these patients is not restricted merely to the vasopressor properties of ATII, but also includes its potential ability to block SARS-CoV-2 cell entry because ATII induces internalization and degradation of angiotensin-converting enzyme 2 (ACE2) receptors, which are used by the SARS-CoV-2 spike protein to enter cells.

The renin-angiotensin-aldosterone system (RAAS) is one of the most important physiologic control systems in the human body, and regulates sodium-water and blood pressure homeostasis. The major effector of the RAAS is the ATII octapeptide.
Renin cleaves angiotensinogen into angiotensin I (ATI), which is converted subsequently to ATII by (ACE) and, to a lesser extent, by other chymases stored in secretory granules of mast cells. Circulating ATII regulates blood pressure and electrolyte balance through its actions on vascular tone, aldosterone secretion, renal sodium handling, thirst, water intake, sympathetic activity, and vasopressin release. ATII exerts its action by binding to 2 main receptors (ATII type 1 receptor [AT1R] and ATII type 2 receptor [AT2R]). Both AT1R and AT2R are transmembrane G-protein-coupled receptors, and have counter-regulatory actions in the cardiovascular and renal systems. In a negative feedback loop, ATII levels regulate and lower renin levels (Fig 1).

RAAS plays a crucial role in cardiocirculatory shock. In the presence of severe hypotension and hypovolemia, several main mechanisms are activated to restore volume and arterial blood pressure—activation of the sympathetic nervous system, release of vasopressin, inhibition of atrial and cerebral natriuretic peptides secretion, increase in renin secretion, and, subsequently, ATII-mediated increase in aldosterone secretion (Fig 1). However, an extreme RAAS activation may become deleterious, leading to increased production of reactive oxygen species, excessive arteriolar vasoconstriction, endothelial dysfunction, and an enhanced procoagulant state. This may contribute to the development of multiorgan failure, including acute respiratory distress syndrome (ARDS) and acute renal injury. On the other hand, endothelial disruption, especially if primarily restricted to the lungs, as in the case of ARDS, causes the reduced expression of ACE, which then leads to a decrease in ATII production. In addition, systemic inflammation also might decrease ACE activity and, subsequently, ATII levels, leading to hyperreninemia. The lack of ACE expression and diminished ATII production are part of the rationale behind the use of exogenous ATII in patients with vasodilatory shock or ARDS.

The first study to investigate the role of ATII as a rescue vasopressor in patients with vasodilatory shock was the ATHOS-Trial in 2014. In this small, single-center, double-blind, pilot randomized clinical trial comparing ATII infusion versus placebo in patients with vasodilatory shock, ATII infusion significantly increased mean arterial pressure (MAP), leading to a concomitant reduction in norepinephrine support. Soon after, a large, international, double-blind, placebo-controlled, randomized clinical trial, the ATHOS-3 trial, confirmed the beneficial effects of ATII. In both trials, ATII improved MAP and other hemodynamics parameters in catecholamine-resistant vasodilatory shock, and displayed a trend toward decreased 28-day mortality. A post hoc analysis of those patients with an ATII-deficiency (identified by a high ATI-ATII ratio) enrolled in the ATHOS-3 study, found that in such patients, ATII significantly decreased mortality. In fact, the relative decrease in ATII plasma levels led to higher sensitivity to ATII stimulation. Because ATII induces catecholamine secretion by the adrenal glands and by postganglionic sympathetic fibers, the relative decrease in ATII levels also can result in a lack of endogenous catecholamines, which further increases the risk or severity of vasodilatory shock.

A post hoc analysis of data from ATHOS-3 also was conducted to evaluate the effect of ATII on renal function in patients who, at randomization, had dialysis-dependent acute kidney injury as a complication of the vasodilatory shock (renal-replacement therapy [RRT]). This study confirmed a higher MAP in the treated group, and found that 28-day mortality was significantly less in the AT-II group than in the placebo group (hazard ratio 0.52; 95% CI 0.30-0.87; p = 0.012). Moreover, patients in the ATII group were more likely to discontinue RRT on day 7 than in patients in the placebo group (38% v 15%), possibly due to a direct effect of ATII on renal microcirculation.

Several trials have used ATII in critically ill patients with COVID-19 with vasodilatory shock (Table 1). In a recent, single-center, compassionate-use case series, the authors used ATII either as a primary or rescue vasopressor in 16 ventilated patients with COVID-19—associated vasodilatory shock, and assessed the course of key physiologic variables during the first 48 hours of treatment. Overall, the administration of ATII was associated with the achievement and maintenance of target MAP, an increase in P_{O_2}/F_{O_2} ratio (P/F ratio), and a decrease in F_{O_2}. Moreover, the authors compared 46 mechanically ventilated patients with COVID-19 receiving ATII therapy with 53 controls. Again, MAP was significantly higher in the ATII-treated group, which also achieved a higher P/F ratio and a decreased risk of liver dysfunction. Furthermore, ATII use was associated with a higher probability of reduced use of RRT. The authors found no association with harm in relation to mortality, length of invasive mechanical ventilation, thromboembolic events, and length of hospital stay. An international, multicenter, registry-based study assessed the impact of ATII therapy on physiologic and patient-centered outcomes in 65 critically-ill patients with COVID-19. During the first 12 hours of infusion, patients treated with ATII had a faster decrease in F_{O_2} and maintained similar MAP levels.

In addition to the established vasopressor properties of ATII, ATII may act as a competitive inhibitor with SARS-CoV-2 for ACE2 binding. Furthermore, ATII binding to AT1R leads to the internalization, downregulation, and lysosome-mediated degradation of ACE2 expressed on the cell surface. Thus, the authors investigated the feasibility and safety of ATII administration in patients not critically-ill with COVID-19 with moderate ARDS outside of the intensive care unit; they observed a median change of 3 points in a 6-category ordinal scale, with clinically relevant improvement in 4 patients at day 28. The main findings on the use of ATII in patients with COVID-19 are summarized in Table 1.

Despite these encouraging results, doubts about the effectiveness and safety of ATII within the management of septic shock have been raised. For example, an excessive amount of ATII would further promote the activation of ATR1, which might lead to a potential extreme peripheral vasoconstriction and promotion of a proinflammatory state that may lead to detrimental effects. Such concerns have been reported in the literature both in acute and chronic situations. Acute adverse outcomes include mainly hypertension and
EXOGENOUS ANGIOTENSIN-II IN SEVERE SARS-COV-2 SEPSIS

ANGIOTENSIN II (ATII) is the major effector of the Renin-Angiotensin-Aldosterone-System (RAAS) implicated in sodium-water homeostasis, fluid and blood pressure regulation. Angiotensin II derives from enzymatic cleavages of angiotensin I by ACE enzymes, primarily expressed on pulmonary endothelial cells.

METHODS

We report the results of the most recent studies and of our experience on the use of ATII both as antiviral and rescue vasopressor agent in COVID-19 patients.

We identified five studies. Four of them were single-center prospective observational studies, only one was an international multicenter, register-based study.

We focus on the capability of ATII in preventing disease progression, increasing MAP, improving oxygenation and survival in treated patients and assessing for any side effects of this drug.

RESULTS

Angiotensin II (ATII) appears to be a safe agent with most of the studies showing no major complications related to ATII-infusion. In critically-ill COVID-19 patients with vasodilatory shock, ATII-infusion led to a significant increase in median arterial pressure (MAP) and P/F ratio with associated faster decrease in FIO2. ATII was also associated with an improvement in renal and hepatic function. However further studies and larger RCT are required to better understand its role in this setting.

Fig 1. Rationale for the use of exogenous angiotensin-II in severe SARS-CoV2 sepsis. ACE, angiotensin-converting enzyme; ARDS, acute respiratory distress syndrome.
vasoconstriction-associated organ damage and acute vascular injury. Chronic adverse effects of ATII include the development of cardiac hypertrophy and fibrosis. Moreover, the timing of ATII administration also may alter its effect. According to Salgado et al, ATII may provide benefit only in case of early administration, whereas it may be detrimental and proinflammatory if septic shock already is advanced. However, the findings of the ATHOS-3 study suggested otherwise, and no studies showing a detrimental effect on clinically relevant outcomes have been published so far.

### Table 1
Main Trials on ATII in COVID-19

| Study | Type of Study | Intervention | Study Population | Results / Harm, Length of Stay in Hospital, and Mortality |
|-------|---------------|--------------|------------------|----------------------------------------------------------|
| Heinicke et al 2020<sup>24</sup> | Single-center prospective observational study | Intravenous ATII administration to severe patients with COVID-19 | 6 patients with severe COVID-19: 4 with severe vasodilatory shock, 2 without | Study interrupted because 5 out of the first 6 patients died during or shortly after ATII administration. No improvement in respiratory parameters. No controls. No antiviral effect observed. 5 out of 6 patients treated with ATII administration died. |
| Morselli et al 2020<sup>23</sup> | Single-center prospective observational study | Intravenous ATII administration as antiviral drug | 7 patients with moderate COVID-19–related ARDS in non-ICU setting | No patients developed major complications related to ATII administration. One patient had a mild cutaneous hand rash. At day 28, the median change in the 6-category ordinal scale was +3, with clinically relevant improvement in 4 patients (57%). |
| Serpa Neto et al 2021<sup>21</sup> | Prospective, international, multicenter, registry-based study | ATII either as second-line vasopressor in addition to norepinephrine or solely as first-line agent | Critically ill patients with COVID-19 (65 treated vs 67 controls) | ATII group had a faster decrease in FIO2 and similar MAP levels during the first 12 hours. During the first 3 days after inclusion, P/F ratio was significantly higher, FIO2 remained lower, and MAP was higher in the ATII group. No difference in ventilator-free days at day 28, ICU, hospital-free days at day 28, and ICU and hospital mortality between the 2 groups (53.8% vs 40.3%; p 0.226). The need for RRT and ECMO during hospital stay was similar. The incidence of complications was similar. Absence of early physiologically harm. |
| Zangrillo et al 2020<sup>19</sup> | Single-center prospective observational study | ATII as primary or rescue vasopressor in ventilated COVID-19 with vasodilatory shock | Sixteen invasively ventilated patients with COVID-19 with vasodilatory shock. | MAP and urine output stable, P/F increased significantly with a decrease in FIO2, and PEEP CRP decreased. Lactate and creatinine increased. ATII therapy was not associated with harm in relation to mortality, length of invasive mechanical ventilation, thromboembolic events, and length of stay in hospital. |
| Zangrillo et al 2021<sup>20</sup> | Single-center, case-control, prospective observational study | ATII either as rescue vasopressor or as low dose vasopressor support in mechanically ventilated patients with COVID-19 | Invasively ventilated patients with COVID-19 (46 treated vs 53 controls) | ATII increased MAP and P/F ratio and decreased OR of liver dysfunction and the risk of RRT use in patients with abnormal baseline creatinine. No effect on lactate, urinary output, serum creatinine, CRP, platelet count and thromboembolic complications. |

Abbreviations: ARDS, acute respiratory distress syndrome; ATII, angiotensin-II; CRP, c-reactive protein; ECMO, extracorporeal membrane oxygenation; FIO2, fraction of inspired oxygen; ICU, intensive care unit; MAP, mean arterial pressure; OR, odds ratio; PEEP, positive end-expiratory pressure; P/F ratio, P.O2/F.IO2 ratio; Pts, patients; RRT, renal replacement therapy.
Finally, important reassuring signals on the use of ATII administration in patients with COVID-19 have been provided indirectly by the recent interruption for safety concerns of the Randomized Embedded Multifactorial Adaptive Platform for Community-Acquired Pneumonia (REMAP-CAP) adaptive trial involving the ACE inhibitor / angiotensin-receptor blocker domain in critically ill patients, which suggested harm from either decreasing ATII generation (ACE inhibitors) or blocking its action (angiotensin-receptor blockers).

Conclusions

ATII is an effective vasoconstrictor for vasoplegic patients, according to several trials. Moreover, ATII has been studied as a vasopressor agent in a few patients with COVID-19 in the intensive care unit, with encouraging results, even though further studies are required in this setting. Finally, based on limited available data, further investigations of ATII in several settings and, potentially, as a primary vasopressor appear justified.

Conflict of Interest

Alexander Zarbock received honorariums and research grants from Fresenius, Baxter, Astellas, AM Pharma, Paion, Guard Therapeutics, Novartis, Bayer, BioMerieux, GIF, BMBF, and DFG. Giovanni Landoni received speaker fees from Paion.

References

1. Arendt M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323:1612–4.
2. Senatore F, Jagadeesh G, Rose M, et al. FDA approval of angiotensin II for the treatment of hypotension in adults with distributive shock. Am J Cardi- ovasc Drugs 2019;19:11–20.
3. Khanna A, English SW, Wang XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017;377:419–30.
4. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol 2020;5:562–9.
5. Deshotels MR, Xia H, Siriamula S, et al. Angiotensin II mediates angioten- sin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor–dependent mechanism. Hypertension 2014;64:1368–75.
6. Fyhruquist F, Sajijunnah O. Renin-angiotensin system revisited. J Intern Med 2008;264:224–36.
7. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediat- ing physiological and pathogenic actions of angiotensin II. Mol Endocrinol 2006;20:953–70.
8. Meersch M, Weiss R, Massoth C, et al. The association between angioten- sin II and renin kinetics in patients after cardiac surgery. Anesth Analg 2022;134:1002–9.
9. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: New roles in inflammation, immunology and aging. EMBO Mol Med 2010;2:247–57.
10. Rolih CA, Ober KP. The endothelial response to critical illness. Med Clin North Am 1995;79:211–24.
11. Correa TD, Takala J, Jakob SM. Angiotensin II in septic shock. Crit Care 2015;19:98.
12. Suzuki Y, Ruiz-Ortega M, Lorenzo O, et al. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003;35:881–900.
13. Laghiham D, Jozwiak M, Nguyen LS. Renin-angiotensin-aldosterone system and immunomodulation: A state-of-the-art review. Cells 2021;10:1767.
14. Orfanos SE, Chen XL, Ryan JW, et al. Assay of pulmonary microvascular endothelial angiotensin-converting enzyme in vivo: Comparison of three probes. Toxicol Appl Pharmacol 1994;124:99–111.
15. Chawla LS, Ostermann M, Forni L, et al. Broad spectrum vasopressors: A new approach to the initial management of septic shock? Crit Care 2019;23:124.
16. Chawla LS, Busse L, Brash-Mitchell E, et al. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): A pilot study. Crit Care 2014;18:534.
17. Ham KR, Boldt DW, McCurdy MT, et al. Sensitivity to angiotensin II dose in patients with vasodilatory shock: A prespecified analysis of the ATHOS-3 trial. Ann Intensive Care 2019;9:63.
18. Tumlin JA, Murugan R, Deane AM, et al. Outcomes in patients with vaso- dilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med 2018;46:949–57.
19. Zangrillo A, Landoni G, Beretta L, et al. Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series. Crit Care 2020;24:227.
20. Zangrillo A, Colombo S, Scandoglio AM, et al. Angiotensin II infusion and markers of organ function in invasively ventilated COVID-19 patients. Crit Care Resusc 2021;23:215–24.
21. Serpa Neto A, Landoni G, Ostermann M, et al. Angiotensin II infusion in COVID-19: An international, multicenter, registry-based study. J Med Virol 2022;94:2079–88.
22. Busse LW, Chow JH, McCurdy MT, et al. COVID-19 and the RAAS-a potential role for angiotensin II? Crit Care 2020;24:136.
23. Morselli F, Vitali G, Brisschi E, et al. Feasibility and safety of angiotensin II administration in general ward patients during COVID-19 pandemic: A case series. Crit Care Resusc 2020;22:388–90.
24. Heinicke U, Adam E, Sonntagbauer M, et al. Angiotensin II treatment in COVID-19 patients: More risk than benefit? A single-center experience. Crit Care 2020;24:409.
25. Larkin JE, Frank BC, Gaspard RM, et al. Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol Genomics 2004;18:152–66.
26. Forrester SJ, Booz GW, Sigmund CD, et al. Angiotensin II signal transduc- tion: An update on mechanisms of physiology and pathophysiology. Physiol Rev 2018;98:1627–738.
27. Salgado DR, Rocco JR, Silva E, et al. Modulation of the renin-angiotensin-aldosterone system in sepsis: A new therapeutic approach? Expert Opin Ther Targets 2010;14:11–20.